Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) is set to release its financial results for the fourth quarter and full year ending December 31, 2020, on March 16, 2021, after market close. The conference call will be led by CEO Ron Rocca and CFO Kamal Adawi at 4:30 PM ET. Interested participants can join via phone or webcast through the Exagen investor relations website. A replay will be available until March 23, 2021. Exagen focuses on innovative testing products for autoimmune diseases, aiming to enhance provider capabilities in diagnosing and managing conditions like rheumatoid arthritis and lupus.

Positive

• Focus on innovative testing products under AVISE® brand.
• Goal to improve patient care in autoimmune diseases.

Negative

• None.

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/

A replay of the conference call will be available until Tuesday, March 23, 2021 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13716870.   Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

CONTACTS:

Investors

Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838

Company Contact

Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com 
760.477.5514

FAQ

When will Exagen Inc. announce its financial results for Q4 and full year 2020?

Exagen Inc. will announce its financial results on March 16, 2021, after market close.

What time is the conference call for Exagen's financial results?

The conference call is scheduled for 4:30 PM Eastern Time on March 16, 2021.

How can I access the Exagen conference call?

The conference call can be accessed by dialing (877) 407-3982 for U.S. calls or (201) 493-6780 internationally, or via the webcast link on Exagen's investor relations website.

How long will the replay of Exagen's conference call be available?

The replay of the conference call will be available until March 23, 2021, at 11:59 PM Eastern Time.

What is Exagen's focus in the healthcare market?

Exagen is focused on transforming care for patients with autoimmune diseases through innovative testing solutions.